tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PHRRF Stock Latest News

PharmaTher Targets Early Entry Into Canada’s Emerging Generic Semaglutide Market
Company AnnouncementsPharmaTher Targets Early Entry Into Canada’s Emerging Generic Semaglutide Market
5d ago
PharmaTher Extends Microneedle Patch Platform to GLP-1 Obesity Market
PremiumCompany Announcements
PharmaTher Extends Microneedle Patch Platform to GLP-1 Obesity Market
24d ago
PharmaTher CEO Targets 2026 Asset Monetization After Ketamine ANDA Sale and FDA Win
PremiumCompany Announcements
PharmaTher CEO Targets 2026 Asset Monetization After Ketamine ANDA Sale and FDA Win
1M ago
PharmaTher Sells Ketamine ANDA to Focus on Long-Acting Injectable Program
PremiumCompany Announcements
PharmaTher Sells Ketamine ANDA to Focus on Long-Acting Injectable Program
2M ago
PharmaTher Secures Rights to Long-Acting Ketamine Program for Neuropsychiatric Disorders
PremiumCompany Announcements
PharmaTher Secures Rights to Long-Acting Ketamine Program for Neuropsychiatric Disorders
3M ago
PharmaTher Poised for Growth as FDA Prioritizes Ketamine
PremiumCompany AnnouncementsPharmaTher Poised for Growth as FDA Prioritizes Ketamine
4M ago
PharmaTher Advances Phase 3 FDA Package for Ketamine in Parkinson’s Treatment
Premium
Company Announcements
PharmaTher Advances Phase 3 FDA Package for Ketamine in Parkinson’s Treatment
4M ago
PharmaTher Launches AI Platform to Expand Ketamine Portfolio
Premium
Company Announcements
PharmaTher Launches AI Platform to Expand Ketamine Portfolio
4M ago
PharmaTher Advances Ketamine Program for Parkinson’s Disease Dyskinesia
PremiumCompany Announcements
PharmaTher Advances Ketamine Program for Parkinson’s Disease Dyskinesia
4M ago
Psychedelic: Enveric announces EB-003 manufacturing milestones
PremiumThe Fly
Psychedelic: Enveric announces EB-003 manufacturing milestones
4M ago
ENVB
NRXP
PharmaTher Advances Ketamine Strategy with Strategic Asset Sale
PremiumCompany Announcements
PharmaTher Advances Ketamine Strategy with Strategic Asset Sale
4M ago
PharmaTher provides update on ketamine development, commercial strategy
PremiumThe Fly
PharmaTher provides update on ketamine development, commercial strategy
4M ago
PharmaTher Sells Ketamine ANDA with Potential $25 Million Upside
PremiumCompany AnnouncementsPharmaTher Sells Ketamine ANDA with Potential $25 Million Upside
4M ago
PharmaTher announces sales of ketamine ANDA
Premium
The Fly
PharmaTher announces sales of ketamine ANDA
4M ago
PharmaTher Advances Ketamine Patch for Non-Opioid Pain Relief
Premium
Company Announcements
PharmaTher Advances Ketamine Patch for Non-Opioid Pain Relief
5M ago
PharmaTher Advances U.S. Market Strategy Following FDA Approval of KETARx™
PremiumCompany Announcements
PharmaTher Advances U.S. Market Strategy Following FDA Approval of KETARx™
5M ago
PharmaTher provides update following FDA approval of ketamine
PremiumThe Fly
PharmaTher provides update following FDA approval of ketamine
5M ago
Psychedelic: atai Life Sciences, Cybin report earnings results
PremiumThe Fly
Psychedelic: atai Life Sciences, Cybin report earnings results
6M ago
ATAI
CYBN
PharmaTher Receives FDA Approval for KETARx™, Paving Way for New Opportunities
PremiumCompany Announcements
PharmaTher Receives FDA Approval for KETARx™, Paving Way for New Opportunities
6M ago
PharmaTher issues letter to shareholders
PremiumThe FlyPharmaTher issues letter to shareholders
6M ago
PharmaTher’s KETARx™ Gains FDA Approval, Paving Way for Expansion
Premium
Company Announcements
PharmaTher’s KETARx™ Gains FDA Approval, Paving Way for Expansion
6M ago
PharmaTher announces FDA approval of ketamine product
Premium
The Fly
PharmaTher announces FDA approval of ketamine product
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >